Skip to main content
SpringerLink
Log in

Active Hydroxymetabolites of Antidepressants

Emphasis on E-10-Hydroxy-Nortriptyline

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Hydroxymetabolites of the antidepressants nortriptyline and desipramine, like the parent drugs, inhibit neuronal uptake of noradrenaline (norepinephrine). In both plasma and cerebrospinal fluid (CSF), the concentrations of the 10-hydroxymetabolites of nortriptyline (10-OH-NT) are usually higher than those of the parent drugs, but there is a pronounced interindividual variation in the plasma concentrations. This shows that during treatment with nortriptyline, hydroxymetabolites exert, at least in some patients, major effects on brain noradrenaline neurons.

Hydroxymetabolites of antidepressants are formed by the polymorphic cytochrome P450 enzyme CYP2D6. Nortriptyline is hydroxylated by this enzyme in a highly stereospecific way to the (−)-enantiomer of E-10-OH-NT. Among Caucasians, 7% are poor metabolisers of the CYP2D6 probe drug debrisoquine. These patients will form very little hydroxymetabolite.

The affinity of E-10-OH-NT for muscarinic acetylcholine receptors in vitro was only one-eighteenth of the affinity of nortriptyline for these receptors. In healthy individuals, nortriptyline decreased saliva flow to a significantly greater extent than either E-10-OH-NT or placebo. In an ultrarapid hydroxylator of nortriptyline treated with very high doses of nortriptyline, the plasma concentration of unconjugated 10-OH-NT was very high without any sign of anticholinergic adverse effects. These results show that hydroxymetabolites of nortriptyline have much less anticholinergic effect than the parent drug.

When racemic E-10-OH-NT per se was given to healthy individuals, the plasma concentration of the (−)-enantiomer was 5-fold higher than that of (+)-E-10-OH-NT. The 2 enantiomers were eliminated in parallel with an elimination half-life of 8 to 10 hours. A combined in vitro and in vivo investigation showed that a mean of 64% of (+)-E-10-OH-NT was glucuronidated in the liver and subsequently eliminated in urine. Of the administered (−)-enantiomer, a mean of 36% was eliminated as glucuronide formed in the intestine and 35% was actively secreted as unchanged form in urine.

Plasma protein binding, determined by ultrafiltration, of the (+)- and (−)-enantiomers of E-10-OH-NT was 54 and 69%, respectively, which is less than that of nortriptyline (92%). The concentration of E-10-OH-NT in CSF was 50% of the concentration of unbound in plasma. There seems to be a stereoselective active transport of E-10-OH-NT from the CSF to blood.

We administered racemic E-10-OH-NT to 5 patients during a major depressive episode. During the study period of 3 weeks, the oral daily dose was increased from 75 to 225mg. The mean depression score decreased by more than 50%, but as the study was noncomparative and nonblinded this needs to be confirmed. Only minor adverse effects were recorded. The concentration of the noradrenaline metabolite 4-hydroxy-3-methoxyphenylglycol (HMPG) in CSF decreased significantly (by a mean of 18%). Therefore, at the doses given, there was inhibition of noradrenaline uptake in central noradrenaline neurons.

Hydroxymetabolites might contribute to biochemical and clinical effects during treatment with antidepressants. Compared with the parent drug, the most investigated metabolite E-10-OH-NT has: (i) similar uptake inhibition in noradrenaline neurons; (ii) considerably less anticholinergic adverse effects; (iii) less cardiotoxicity; (iv) less interindividual variation in pharmacokinetics and metabolism; and (v) similar antidepressant effects, although this needs to be confirmed. These results imply that E-10-OH-NT might be a better antidepressant than nortriptyline. Therefore, additional clinical investigations of E-10-OH-NT should be undertaken.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bertilsson L, Mellström B, Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci 1979; 25: 1285–92

    Article  PubMed  CAS  Google Scholar 

  2. Potter WZ, Calil HM, Manian AA, et al. Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychiatry 1979; 14: 601–13

    PubMed  CAS  Google Scholar 

  3. Nordin C, Bertilsson L, Siwers B. CSF and plasma levels of nortriptyline and its 10-hydroxymetabolites. Br J Clin Pharmacol 1985; 20: 411–3

    Article  PubMed  CAS  Google Scholar 

  4. Potter WZ, Rudorfer MV, Lane EA. Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics. In: Usdin E, Åsberg M, Bertilsson L, et al., editors. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984: 373–90

    Google Scholar 

  5. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130–8

    Article  PubMed  CAS  Google Scholar 

  6. Wägner A, Ekqvist B, Bertilsson L, et al. Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci 1984; 35: 1379–83

    Article  PubMed  Google Scholar 

  7. Nordin C, Bertilsson L, Otani K, et al. Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjects. Clin Pharmacol Ther 1987; 41: 97–102

    Article  PubMed  CAS  Google Scholar 

  8. Nilvebrant L, Nordin C. Affinity of nortriptyline and its E-10-hydroxymetabolite for muscarinic receptors. Pharmacol Toxicol 1991; 68: 64–7

    Article  PubMed  CAS  Google Scholar 

  9. Spina E, Birgersson C, von Bahr C, et al. Phenotypic consistency in hydroxylation of desmethyl imipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984; 36: 677–82

    Article  PubMed  CAS  Google Scholar 

  10. Spreux-Varoquaux O, Morin D, Advenir C, et al. Determination of clomipramine and its hydroxylated and demethylated metabolites in plasma and urine by liquid chromatography with electrochemical detection. J Chromatogr 1987; 416: 311–9

    Article  PubMed  CAS  Google Scholar 

  11. Prox A, Breyer-Pfaff U. Amitriptyline metabolites in human urine — identification of phenols, dihydrodiols, glycols and ketones. Drug Metab Disp 1987; 15: 890–6

    CAS  Google Scholar 

  12. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. Eur J Clin Pharmacol 1972; 4: 201–5

    Article  Google Scholar 

  13. Mellström B, Bertilsson L, Säwe J, et al. E- and Z-hydroxylation of nortriptyline in man — relationship to polymorphic hydroxylation of debrisoquine. Clin Phamacol Ther 1981; 30: 189–93

    Article  Google Scholar 

  14. Gram LF, Brøsen K, Kragh-Sørensen P, et al. Steady-state plasma levels of E- and Z-10-hydroxynortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989; 11: 508–14

    Article  PubMed  CAS  Google Scholar 

  15. Heimstad E, Edvardsen Ø, Dahl SG. Molecular structure and dynamics of the four 10-hydroxynortriptyline isomers. Neuropsychopharmacology 1992; 6: 137–44

    PubMed  CAS  Google Scholar 

  16. Ziegler VE, Fuller TA, Biggs JT. Nortriptyline and 10-hydroxynortriptyline plasma concentrations. J Pharm Pharmacol 1976; 28: 849–50

    Article  PubMed  CAS  Google Scholar 

  17. Young RC, Alexopoulos GS, Shamoian CA, et al. Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin Pharmacol Ther 1984; 35: 540–4

    Article  PubMed  CAS  Google Scholar 

  18. Borgå O, Palmér L, Linnarsson A, et al. Quantitative determination of nortriptyline and desmethylnortriptyline in human plasma by combined gas chromatography-mass spectrometry. Anal Lett 971; 4: 837–49

  19. Mellström B, Braithwaite R. Ion-pair liquid chromatography of amitriptyline and metabolites in plasma. J Chromatogr 1978; 157: 379–85

    Article  PubMed  Google Scholar 

  20. Dahl-Puustinen M-L, Perry Jr TL, Dumont E, et al. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. Clin Pharmacol Ther 1989; 45: 650–6

    Article  PubMed  CAS  Google Scholar 

  21. Bertilsson L, Nordin C, Otani K, et al. Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects with some observation on pharmacodynamic effects. Clin Pharmacol Ther 1986; 40: 261–7

    Article  PubMed  CAS  Google Scholar 

  22. Nusser E, Nill K, Breyer-Pfaff U. Enantioselective formation and disposition of (E)- and (Z)-10-hydroxynortriptyline. Drug Metab Disp 1988; 16: 509–11

    CAS  Google Scholar 

  23. Nusser E, Nill K, Breyer-Pfaff U. Enantiomer analysis of E- and Z-10-hydroxyamitriptyline in human urine. J Chromatogr 1990; 528: 163–71

    Article  PubMed  CAS  Google Scholar 

  24. Sutfin TA, Jusko WJ. High-performance liquid chromatographic assay for imipramine, desipramine and their 2-hydroxylated metabolites. J Pharm Sci 1979; 68: 703–5

    Article  PubMed  CAS  Google Scholar 

  25. Balant-Gorgia AE, Balant LP, Genet CH, et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986; 31: 449–55

    Article  PubMed  CAS  Google Scholar 

  26. Alexanderson B, Evans DAP, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 1969; 4: 764–8

    Article  PubMed  CAS  Google Scholar 

  27. Alexanderson B. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins. Eur J Clin Pharmacol 1973; 6: 44–53

    Article  PubMed  CAS  Google Scholar 

  28. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–6

    Article  PubMed  CAS  Google Scholar 

  29. Bertilsson L, Eichelbaum M, Mellström B, et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673–7

    Article  PubMed  CAS  Google Scholar 

  30. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350–8

    Article  PubMed  CAS  Google Scholar 

  31. Dahl ML, Nordin C, Bertilsson L. Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate and in patients treated with nortriptyline. Ther Drug Monit 1991; 13: 189–94

    Article  PubMed  CAS  Google Scholar 

  32. Pfandl B, Mörike K, Winne D, et al. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica 1992; 22: 721–30

    Article  PubMed  CAS  Google Scholar 

  33. Nordin C, Siwers B, Benitez J, et al. Plasma concentrations of nortriptyline and its 10-hydroxymetabolite in depressed patients — relationship to the debrisoquine metabolic ratio. Br J Clin Pharmacol 1985; 19: 832–5

    Article  PubMed  CAS  Google Scholar 

  34. Eichelbaum M, Bertilsson L, Säwe J, et al. Polymorphic oxidaion of sparteine and debrisoquine. Related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31: 184–6

    Article  PubMed  CAS  Google Scholar 

  35. Balant-Gorgia AE, Schulz P, Dayer P, et al. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 1982; 232: 215–22

    Article  PubMed  CAS  Google Scholar 

  36. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537–47

    Article  PubMed  Google Scholar 

  37. Bertilsson L, Åberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983; 15: 388–90

    Article  PubMed  CAS  Google Scholar 

  38. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388–97

    Article  PubMed  CAS  Google Scholar 

  39. Bertilsson L, Mellström B, Sjöqvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications. Lancet 1981; 1: 560–1

    Article  PubMed  CAS  Google Scholar 

  40. Sjöqvist F, Bertilsson L. Clinical pharmacology of antidepressant drugs: pharmacogenetics. In: Usdin E, Åsberg M, Bertilsson L, et al., editors. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984: 359–72

    Google Scholar 

  41. Bertilsson L, Åsberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine — a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478–80

    Article  PubMed  CAS  Google Scholar 

  42. Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993; 341: 63

    Article  PubMed  CAS  Google Scholar 

  43. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825–9

    Article  PubMed  CAS  Google Scholar 

  44. Malmgren R, Åberg-Wistedt A, Bertilsson L. Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. Psychopharmacology 1987; 92: 169–72

    Article  PubMed  CAS  Google Scholar 

  45. Nordin C, Bertilsson L, Siwers B. Clinical and biochemical effects during treatment of depression with nortriptyline — the role of 10-hydroxynortriptyline. Clin Pharmacol Ther 1987; 42: 10–9

    Article  PubMed  CAS  Google Scholar 

  46. Snyder SH, Yamamura HI. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977; 34: 236–9

    Article  PubMed  CAS  Google Scholar 

  47. Nordin C, Bertilsson L. Disposition and effects of E-10-hydroxynortriptyline — an active metabolite of nortriptyline. In: Lerer B, Gershon S, editors. New directions in affective disorders. New York: Springer-Verlag, 1989: 620–2

    Chapter  Google Scholar 

  48. Young RC, Alexopoulos GS, Shamonian CA, et al. Heart failure associated with high plasma 10-hydroxynortriptyline levels. Am J Psychiatry 1984; 141: 432–3

    PubMed  CAS  Google Scholar 

  49. Young RC, Alexopoulos GS, Shamonian CA, et al. Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients. Am J Psychiatry 1985; 142: 866–8

    PubMed  CAS  Google Scholar 

  50. Young RC. Hydroxylated metabolites of antidepressants. Psychopharmacol Bull 1991; 27: 521–32

    PubMed  CAS  Google Scholar 

  51. Schneider LS, Cooper TB, Severson J, et al. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol 1988; 8: 402–8

    Article  PubMed  CAS  Google Scholar 

  52. Pollock BG, Everett G, Perel JM. Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacology 1992; 6: 1–10

    PubMed  CAS  Google Scholar 

  53. Young RC, Mattis S, Alexopoulos GS, et al. Verbal memory and plasma drug concentrations in elderly depressives treated with nortriptyline. Psychopharmacol Bull 1991; 27: 291–4

    PubMed  CAS  Google Scholar 

  54. Gram LF, Kragh-Sørensen P, Kristensen CB, et al. Plasma level monitoring of antidepressants: Theoretical basis and clinical application. In: Usdin E, Åsberg M, Bertilsson L, et al., editors. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984: 399–411

    Google Scholar 

  55. Åsberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971; 3: 331–4

    Article  PubMed  Google Scholar 

  56. Reisby N, Gram LF, Bech P, et al. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology 1977; 54: 263–72

    Article  PubMed  CAS  Google Scholar 

  57. Young RC, Alexopoulos GS, Shindledecker R, et al. Plasma 10-hydroxynortriptyline and therapeutic response in geriatric depression. Neuropsychopharmacology 1988; 1: 213–5

    Article  PubMed  CAS  Google Scholar 

  58. Nelson JC, Bock JL, Jatlow PI. Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin Pharmacol Ther 1983; 33: 183–9

    Article  PubMed  CAS  Google Scholar 

  59. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9

    Article  PubMed  CAS  Google Scholar 

  60. Nordin C, Collste P, Otani K, et al. Effects of nortriptyline and its 10-hydroxymetabolite on plasma noradrenaline (NA) concentrations, heart rate and blood pressure during intravenous NAinfusion. Methods Find Exp ClinPharmacol 1987; 9: 691–6

    CAS  Google Scholar 

  61. Dumont E, von Bahr C, Perry Jr TL, et al. Glucuronidation of the enantiomers of E-10-hydroxynortriptyline in human and rat liver microsomes. Pharmacol Toxicol 1987; 61: 335–41

    Article  PubMed  CAS  Google Scholar 

  62. Dahl-Puustinen M-L, Dumont E, Bertilsson L. Glucuronidation of E-10-hydroxynortriptyline in human liver, kidney and intestine — organ-specific differences in enantioselectivity. Drug Metab Disp 1989; 17: 433–6

    CAS  Google Scholar 

  63. Breyer-Pfaff U, Gaertner HJ, Krenter F, et al. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 1982; 76: 240–4

    Article  PubMed  CAS  Google Scholar 

  64. Baumann P, Jonzier-Perey M, Koeb L, et al. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychpharmacol 1986; 1: 102–12

    Article  CAS  Google Scholar 

  65. Rollins D, Alván G, Bertilsson L, et al. Interindividual differences in the demethylation of amitriptyline. Clin Pharmacol Ther 1980; 28: 121–9

    Article  PubMed  CAS  Google Scholar 

  66. Bertilsson L, Otani K, Dahl M-L, et al. Stereoselective efflux of E-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients. Pharmacol Toxicol 1991; 68: 100–3

    Article  PubMed  CAS  Google Scholar 

  67. Nordin C. CSF/Plasma ratio of 10-hydroxynortriptyline is influenced by sex and body height. Psychopharmacology 1993; 113: 222–4

    Article  PubMed  CAS  Google Scholar 

  68. Nordin C, Bertilsson L, Dahl ML, et al. Treatment of depression with E-10-hydroxynortriptyline — a pilot study on biochemical effects and pharmacokinetics. Psychopharmacology 1991; 103: 287–90

    Article  PubMed  CAS  Google Scholar 

  69. Bertilsson L. 5-Hydroxyindoleacetic acid in cerebrospinal fluid — methodological and clinical aspects. Life Sci 1987; 41: 821–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Neurosciences and Family Medicine, Division of Psychiatry and Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at the Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden

    Conny Nordin &  Leif Bertilsson

Authors
  1. Conny Nordin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leif Bertilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nordin, C., Bertilsson, L. Active Hydroxymetabolites of Antidepressants. Clin. Pharmacokinet. 28, 26–40 (1995). https://doi.org/10.2165/00003088-199528010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199528010-00004

Keywords

Search

Navigation